DERM on RheumNow (October 2025)

DERM on RheumNow PODCAST (October 2025)
Skin important Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects. Features Dr. Jack Cush, Editor at RheumNow.com. 
SHOW NOTES
1. Skin Biopsies to Predict Scleroderma Outcomes? 
2. Fibromyalgia in PsO & PsA is linked to greater treatment complexity and shorter biologic therapy survival. Retro matched 1:4 cohort study 61K PsO& 244K controls. FM prevalence 3.3% (OR 1.45). In PsA w/ FM, req more biologics w/ decr biologic survival (6 vs 10yrs) w/ incr switching (HR 1.82) https://buff.ly/TCc6Kc8
3. Guselkumab FDA Approved for Pediatric Psoriasis and Psoriatic Arthritis  https://rheumnow.com/news/guselkumab-fda-approved-pediatric-psoriasis-and-psoriatic-arthritis   
4. Sonelokimab (SLK) is a nanobody that inhibits IL-17 A&F. Phase 2 ARGO trial 207 active PsA pts Rx w/ SLK 120-mg or 60-mg q4wks or PBO or adalimumab. ACR50 at wk 12 was 60-mg WI=46%; 120-mg WI=46%; PBO 20%. PASI90: 60mg 77% vs 120mg 59% vs PBO 15% https://t.co/ra0NqvUEru https://t.co/FXT6kkXUzH  
5. Turkish study of 799 psoriasis pts - 30% had concurrent onset PsO & PsA & in 70% there was a long transition time (~13 yrs) from PsO-to-PsA. Factors assoc w/ prolonged interval included Depression, fatigue, scalp PsO(OR 7), nail PsO (3.2), +Fhx & enthesitis ever (OR 2) https://t.co/wqtSbeQ2vz
6. Mediterranean Diet Efficacy in Psoriasis  
7. Gender Complexities in Psoriatic Arthritis Treatment Outcomes